Release Date: 27-Sep-2021
US FDA granted the orphan designation to NNZ-2591 for treating Prader-Willi, a neurodevelopmental disorder. Neuren Pharmaceuticals outcome of the trial using a mouse model of Prader-Willi syndrome, which saw treatment for six weeks normalize fat mass, insulin levels and all behavioral deficits has shown a positive result.
In Infants this disease causes low muscle tone and faces difficulty in feeding and later develops a range of intellectual and learning disabilities, growth hormone deficiency, sleep disturbances and speech difficulties, along with constant hunger and difficulty controlling emotions.